Vanda Pharmaceuticals Inc. (VNDA): Price and Financial Metrics

Vanda Pharmaceuticals Inc. (VNDA): $4.11

0.22 (+5.66%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

B

Add VNDA to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#35 of 365

in industry

VNDA Price/Volume Stats

Current price $4.11 52-week high $7.00
Prev. close $3.89 52-week low $3.30
Day low $3.91 Volume 1,372,200
Day high $4.19 Avg. volume 980,095
50-day MA $3.99 Dividend yield N/A
200-day MA $4.66 Market Cap 236.48M

VNDA Stock Price Chart Interactive Chart >

VNDA POWR Grades

  • Value is the dimension where VNDA ranks best; there it ranks ahead of 99.77% of US stocks.
  • The strongest trend for VNDA is in Stability, which has been heading down over the past 26 weeks.
  • VNDA's current lowest rank is in the Growth metric (where it is better than 0.37% of US stocks).

VNDA Stock Summary

  • For VNDA, its debt to operating expenses ratio is greater than that reported by just 8.66% of US equities we're observing.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.19 for VANDA PHARMACEUTICALS INC; that's greater than it is for only 12.76% of US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, VANDA PHARMACEUTICALS INC is reporting a growth rate of 71.05%; that's higher than 86.37% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to VANDA PHARMACEUTICALS INC are ATEN, MDRX, AYRO, ALKS, and GEOS.
  • Visit VNDA's SEC page to see the company's official filings. To visit the company's web site, go to www.vandapharma.com.

VNDA Valuation Summary

  • VNDA's EV/EBIT ratio is 3.8; this is 73.97% lower than that of the median Healthcare stock.
  • VNDA's EV/EBIT ratio has moved up 11.7 over the prior 216 months.

Below are key valuation metrics over time for VNDA.

Stock Date P/S P/B P/E EV/EBIT
VNDA 2023-12-29 1.1 0.4 20.6 3.8
VNDA 2023-12-28 1.2 0.5 20.8 3.9
VNDA 2023-12-27 1.2 0.5 21.0 4.1
VNDA 2023-12-26 1.1 0.4 19.8 3.3
VNDA 2023-12-22 1.1 0.4 19.4 3.0
VNDA 2023-12-21 1.0 0.4 18.8 2.6

VNDA Growth Metrics

    Its 2 year price growth rate is now at -14.51%.
  • Its 2 year net income to common stockholders growth rate is now at -84.51%.
  • Its year over year revenue growth rate is now at 5.29%.
Over the past 34 months, VNDA's revenue has gone up $16,907,000.

The table below shows VNDA's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-12-31 254.382 31.984 6.275
2022-09-30 257.919 49.175 6.492
2022-06-30 262.696 45.735 10.993
2022-03-31 266.205 59.067 18.072
2021-12-31 268.682 64.214 33.152
2021-09-30 268.316 56.909 34.264

VNDA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • VNDA has a Quality Grade of B, ranking ahead of 90.12% of graded US stocks.
  • VNDA's asset turnover comes in at 0.483 -- ranking 88th of 682 Pharmaceutical Products stocks.
  • NEOG, CLVS, and AMRN are the stocks whose asset turnover ratios are most correlated with VNDA.

The table below shows VNDA's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.483 0.904 0.107
2021-06-30 0.479 0.904 0.105
2021-03-31 0.482 0.904 0.107
2020-12-31 0.486 0.906 0.086
2020-09-30 0.484 0.904 0.073
2020-06-30 0.493 0.900 0.085

VNDA Price Target

For more insight on analysts targets of VNDA, see our VNDA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $24.00 Average Broker Recommendation 1 (Strong Buy)

Vanda Pharmaceuticals Inc. (VNDA) Company Bio


Vanda Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders. The company was founded in 2002 and is based in Washington, the District of Columbia.


VNDA Latest News Stream


Event/Time News Detail
Loading, please wait...

VNDA Latest Social Stream


Loading social stream, please wait...

View Full VNDA Social Stream

Latest VNDA News From Around the Web

Below are the latest news stories about VANDA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate VNDA as an investment opportunity.

Calculating The Fair Value Of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

Key Insights Using the 2 Stage Free Cash Flow to Equity, Vanda Pharmaceuticals fair value estimate is US$4.84 Vanda...

Yahoo | December 8, 2023

Vanda Pharmaceuticals Acquires U.S. and Canadian Rights to PONVORY® (ponesimod), a Selective S1P1R Modulator Approved for Patients with Relapsing Multiple Sclerosis

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it has acquired U.S. and Canadian rights to PONVORY® (ponesimod) from Actelion Pharmaceuticals Ltd. (Janssen), a Johnson & Johnson Company. PONVORY® is approved by the U.S. Food and Drug Administration (FDA) and Health Canada to treat adults with relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. PONVORY® has a proven safe

Yahoo | December 7, 2023

Vanda (VNDA) Rises as FDA Accepts NDA for Gastroparesis Drug

The FDA accepts Vanda's (VNDA) new drug application ("NDA") for tradipitant for treating the symptoms of gastroparesis. The company's shares rise in after-hours trading.

Yahoo | December 5, 2023

Vanda Pharmaceuticals Announces that U.S. Food and Drug Administration Accepts New Drug Application for Tradipitant for the Treatment of Gastroparesis

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of Vanda's New Drug Application (NDA) for tradipitant for the treatment of symptoms of gastroparesis.

Yahoo | December 4, 2023

One Analyst Thinks Vanda Pharmaceuticals Inc.'s (NASDAQ:VNDA) Revenues Are Under Threat

The analyst covering Vanda Pharmaceuticals Inc. ( NASDAQ:VNDA ) delivered a dose of negativity to shareholders today...

Yahoo | November 11, 2023

Read More 'VNDA' Stories Here

VNDA Price Returns

1-mo -8.05%
3-mo -2.61%
6-mo -4.86%
1-year -38.75%
3-year -72.38%
5-year -77.66%
YTD -2.61%
2023 -42.90%
2022 -52.90%
2021 19.41%
2020 -19.93%
2019 -37.20%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!